Calabrò, L. et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, ...
Calabrò, L. et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, ...
Our website uses cookies to improve your experience. Learn more about: Cookie Policy